Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor FDA class
- Main trialPhase 1
- “The purpose of this study is to evaluate the bioequivalence between Orfadin 20 mg and 10 mg capsules in healthy volunteers.”In the company’s words, NCT01857362 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | Jun 2013 | Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026